First human test: can new weight drug work safely for people with kidney problems?
NCT ID NCT07443059
Summary
This is an early safety study for a new injectable drug called ZT002, being developed for overweight and obesity. It aims to understand how the drug is processed by the body in 40 people with different levels of kidney function, compared to people with normal kidneys. The main goal is to measure drug levels in the blood and check for side effects after a single dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital Of Shandong First Medical Unversity
Jinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.